Ju H. Oh
Seoul, Republic of Korea
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications
Biomarker-Driven Optimization of Saponin Therapy in MASLD: From Mouse Models to Human Liver Organoids.
Journal: Antioxidants (Basel, Switzerland)
Published: June 23, 2025
Adenosine triphosphate-binding pocket inhibitor for mixed lineage kinase domain-like protein attenuated alcoholic liver disease via necroptosis-independent pathway.
Journal: World journal of gastroenterology
Published: May 15, 2024
Ticagrelor, but Not Clopidogrel, Attenuates Hepatic Steatosis in a Model of Metabolic Dysfunction-Associated Steatotic Liver Disease.
Journal: Nutrients
Published: February 07, 2024
Novel Inhibitor of Mixed-Lineage Kinase Domain-Like Protein: The Antifibrotic Effects of a Necroptosis Antagonist.
Journal: ACS pharmacology & translational science
Published: June 28, 2023
Hepatic stellate cells activate and avoid death under necroptosis stimuli: Hepatic fibrosis during necroptosis.
Journal: Journal of gastroenterology and hepatology
Published: May 14, 2023
Discovery biomarker to optimize obeticholic acid treatment for non-alcoholic fatty liver disease.
Journal: Biology direct
Published: January 28, 2023
Regulation of Hepatocyte Nuclear Factor 4α Attenuated Lipotoxicity but Increased Bile Acid Toxicity in Non-Alcoholic Fatty Liver Disease.
Journal: Life (Basel, Switzerland)
Published: September 26, 2022
Preclinical investigation of patient-derived cervical cancer organoids for precision medicine.
Journal: Journal of gynecologic oncology
Published: August 29, 2022
Peripheral blood mononuclear cell mitochondrial copy number and adenosine triphosphate inhibition test in NAFLD.
Journal: Frontiers in endocrinology
Published: June 13, 2022
Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF- κB signaling pathways.
Journal: Clinical and molecular hepatology
Published: March 10, 2022
Last Updated: 09/26/2026